Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.
Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...
1 Day HIVE 17.77% DJIA 1.01% S&P Mid Cap 400 0.58% Technology 1.09% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback